Chimeric antigen receptor(CAR) T-cell therapy has shown remarkable effects and promising prospects in patients with refractory or relapsed malignancies, pending further progress in the next-generation CAR T cells with more optimized structure, enhanced efficacy and reduced toxicities. The clustered regulatory interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9) technology holds immense promise for advancing the field owing to its flexibility, simplicity, high efficiency and multiplexing in precise genome editing. Herein, we review the applications and explorations of CRISPR/Cas9 technology in constructing allogenic universal CAR T cells, disrupting inhibitory signaling to enhance potency and exploration of safer and more controllable novel CAR T cells.

中文翻译：

---

CRISPR / Cas9在CAR T细胞治疗中的应用和探索。

嵌合抗原受体（CAR）T细胞疗法在难治性或复发性恶性肿瘤患者中已显示出显着疗效，并具有广阔的前景，其下一代CAR T细胞的更优化结构，更高的功效和更低的毒性尚待进一步发展。簇状调控间隔的短回文重复/ CRISPR结合蛋白9（CRISPR / Cas9）技术因其灵活性，简单性，高效性和在精确的基因组编辑中的多重性而在推进该领域方面具有广阔的前景。在本文中，我们综述了CRISPR / Cas9技术在构建同种异体通用CAR T细胞，破坏抑制性信号传导以增强效能方面的应用和探索，以及对更安全和可控的新型CAR T细胞的探索。